Induced pluripotent stem (iPS) cells present a seminal discovery in cell biology and promise to support innovative treatments of so far incurable diseases. To translate iPS technology into clinical trials, the safety and stability of these reprogrammed cells needs to be shown. In recent years, different non-viral transposon systems have been developed for the induction of cellular pluripotency, and for the directed differentiation into desired cell types. In this review, we summarize the current state of the art of different transposon systems in iPS-based cell therapies.
Keywords: Cell-based therapy; Cellular reprogramming; Clinical applications; Genetic correction; Induced pluripotent stem cells; Transposons.
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.